Parexel, a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry, today introduced ParexelAI, an innovative, proprietary suite of human-led AI services and capabilities that power Parexel operations and deliver greater speed, quality and efficiency to customers and, ultimately, patients. ParexelAI unifies and leverages the company's full suite of AI capabilities with human oversight and transparency built into every stage.
ParexelAI delivers 50% reduction in site selection process timelines.
30% reduction in clinical study report preparation time in medical writing.
20% reduction in safety literature screening and pharmacovigilance case processing.
Strategic partnerships include Paradigm Health (800+ research sites, 2,100+ provider locations), Weave Bio (60% IND/NDA authoring timeline reduction), and Palantir AI Platform.
Parexel has 22,000+ global employees with 40+ years of proven track record.
Acquired Vitrana for integrated pharmacovigilance platform with intelligent automation.
“ParexelAI represents years of deep technology integration, all in service of helping our customers deliver life-changing treatments to patients,” said Peyton Howell, Chief Executive Officer, Parexel. “We have a responsibility to continually evolve by advancing our capabilities, strengthening our partnerships and innovating in ways that help sponsors run faster, more effective trials. ParexelAI is a natural extension of our corporate growth strategy and our commitment to meeting our customers' current and future needs with confidence.”
“Our tools are designed to automate previously manual work that slows teams down, enabling our experts to increase quality and consistency, surface even more insights for our customers and further improve operational excellence,” said Rob Goodwin, Chief Operating Officer, Parexel. “Supporting our customers at every stage of drug development means they can leverage AI benefits across every aspect of their program, not just in siloed areas.”
“AI delivers its greatest value when it amplifies human expertise,” said Tala Fakhouri, Ph.D., MPH, Chief AI & Regulatory Strategy Officer, Parexel. “Our human-in-the-lead model ensures quality, compliance and patient safety at every stage of the trial lifecycle. With ParexelAI, we're able to apply these insights in real-time to improve every trial. Every efficiency gained and every workflow accelerated serves a single purpose, getting treatments to patients sooner.”
ParexelAI's capabilities are strengthened by partnerships with industry-leading technology companies. Through its strategic partnership with Paradigm Health, Parexel is transforming patient identification and trial access across a network of 800+ research sites and 2,100+ provider locations. Working with Weave Bio, Parexel is reducing Investigational New Drug (IND) and New Drug Application (NDA) authoring timelines by 60% through regulatory automation. Parexel was the first CRO to adopt Palantir's Artificial Intelligence Platform, which serves as the backbone for its AI-enabled clinical operations.
Parexel is a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 22,000+ global employees work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones, and thrive on the tech pulse.